Abbreviations: ASPN, Asporin; BMP1, Bone morphogenic protein 1; CDH11, Cadherin 11; COL10A1, Collagen type X alpha 1; FBN2, Fibrillin 2; RUNX2, Runt-related transcription factor 2; SPP1, Secreted phosphoprotein 1. and RUNX2 on chronic and newly formed keloid compared to NL skin. Our study shows that large keloids in African Americans represent a dysplasia of cutaneous connective tissue towards immature cartilage or bone differentiation. The phenotype is potentially regulated by overexpression of RUNX2. This knowledge may give insights to guide the development of better treatment for the disease in the future.
can be observed in all races, but are more common in native Africans, Hispanics and Asians. [2] In the USA, keloid occurs in ~1/30 of African Americans vs ~1/625 of the overall US population. [3] Although keloid can occur at any age, it is most likely to occur between 10 and 30 years of age. [4] Keloids range in size from small lesions (<1 cm in diameter) to extensive, sometimes massive, tumors (>25 cm in diameter). [5] The etiopathogenesis of keloid is not fully understood. This is in part due to the fact that there are no validated animal models of keloid to study keloid formation or treatment. Many alternative hypotheses exist for keloid formation (all having different therapeutic implications), ranging from dysregulated synthesis of collagen by dermal fibroblasts, to insufficient degradation of deposited matrix, to altered growth factor signalling in disease. [2] Altered endothelial cells that bind or trap platelets, leading to increased release of PDGF-α or TGFβ has been proposed. [6] Altered cross-regulation of cell growth between epidermal and dermal compartments has also been suggested, as keratinocytes synthesize and release many growth factors such as PDGF, FGF and VEGF that regulate underlying connective tissue structure and function. [7] Although there have been several gene expression profiling studies on keloid, most were done in cultured fibroblasts [8] with only a few in vivo studies. [9] [10] [11] Interestingly, one study performed in Japanese subjects and with a limited gene array platform found several upregulated genes associated with chondrogenic and osteogenic connective tissue differentiation. [10] However, studies carried out on other populations, with different array series, have failed to detect these alterations. [11] To further characterize human keloids, we performed transcriptional profiling of biopsies from large chronic keloid lesions and adjacent non-lesional (NL) skin and a newly formed keloid in African
Americans diagnosed with keloids. We studied the Differentially Expressed Genes (DEGs) between chronic keloid and NL skin of the same patient and compared this to the DEGs of a newly formed keloid.
We also performed immunohistochemistry (IHC) and quantitative reverse transcriptase polymerase chain reaction (qRT-PCR) on relevant upregulated genes to confirm increased expression on chronic keloid and newly formed keloid compared to NL skin. Our microarray analysis revealed more than 2000 DEGs and a molecular signal of dysplasia of connective tissue towards immature cartilage and bone differentiation in associated lesions.
| METHODS

| Skin samples
Biopsies from NL, chronic keloid lesion (n=3) and newly formed keloid skin were obtained from African American patients with severe keloids under the Rockefeller University IRB-approved protocols.
Informed consent was obtained, and the study was performed in adherence with the principles of the Declaration of Helsinki. Patients who developed a new keloid from the NL biopsy site were treated with intra-lesional steroid injection. The chronic keloid lesions were present on the patients for more than 20 years while the newly formed keloids on the NL biopsy site developed about 6 weeks after the biopsy was performed.
| Gene Array and qRT-PCR
RNA was extracted from NL, chronic keloid lesion and newly formed keloid biopsies using the RNeasy Mini KIT (Qiagen, Valencia, CA, USA).
RNA was amplified, labelled and hybridized to Affymetrix HGU133 2.0 plus arrays. qRT-PCR was performed using EZ PCR core reagents, primers and probes (Life Technologies, Grand Island, NY, USA) as previously published. [12] Sequences of primers and probes used in this study are found in Table S6A . The results were normalized to HARP housekeeping gene and transformed to base 2 logarithmic values before the analysis. The means and the differences between chronic keloid lesional and NL tissue at each biomarker were assessed with a mixedeffect model (fixed-factor: tissue, random intercept for each patient).
| Immunohistochemistry and Immunofluorescence
Standard procedures were used for IHC and immunofluorescence
(IF) as previously described. [12] For IHC, frozen tissue sections from NL, chronic keloid and newly formed keloid biopsies were stained Table S6B . Biotin-labelled horse anti-mouse (Vector Laboratories, Burlingame, CA, USA) and Biotin-labelled goat anti-rabbit (Vector Laboratories) were used to detect the mouse monoclonal and rabbit polyclonal antibodies, respectively. The staining signal was amplified with avidin-biotin complex (Vector Laboratories) and developed using chromogen 3-amino-9-ethylcarbazole (Sigma-Aldrich, St.
Louis, MO, USA). 
| Statistical analysis
Affymetrix (Santa Clara, CA, USA) CEL files were scanned using software packages Harshlight [13] and array Quality Metrics from R/
Bioconductor (www.bioconductor.org). Expression values (in log2-
scale) were obtained using the GCRMA algorithm. Genes with expression higher than three in at least one sample and standard deviation >0.1 were included in the statistical analysis. Gene expression was modelled using mixed-effect models with group (LS, NL, newly formed)
as a fixed effect and a random intercept for each patient. Resultant Pvalues from the moderated paired t-test were adjusted for multiple hypotheses using the Benjamini-Hochberg procedure, which controls for the false discovery rate (FDR). The data discussed in this publication have been deposited in the Gene Expression Omnibus of the National Center for Biotechnology Information and are accessible through its series accession number GSE92566.
| RESULTS
| Clinical and histology images
Clinical photographs of patients with extensive keloids who enrolled in the study are shown in Figure 1A . Representative histology images of chronic keloid lesion and background NL skin are shown in 
| Microarray analysis showed significant upregulation of genes involved in cartilage and bone development in chronic and newly formed keloids
We observed a wide separation between chronic lesional and NL skin in a PCA plot using the PC-1 axis (Fig. S1A) . A new keloid that Many unanticipated genes encoding cartilage and bone-related proteins were expressed at levels comparable to or higher than dermal collagen genes, for example collagen type I, alpha 1 (COL1A1) was upregulated 31-fold and collagen type III alpha 1 (COL3A1) was upregulated 22-fold, but COL10A1 was upregulated by 48-fold (Table 1A) .
| qRT-PCR analysis confirmed significant upregulation of relevant genes in chronic keloid lesion compared to non-lesional skin
We performed quantitative RT-PCR to confirm upregulation of some 
| Increased protein expression of chondrogenic genes in chronic and new keloid lesion
To confirm the protein expression of selected upregulated genes associated with bone and cartilage formation, we performed IHC staining of ASPN, CDH11, BMP1 and RUNX2 on NL, chronic and newly formed keloid tissue. We observed a strong expression of ASPN, CDH11 and BMP1 in the epidermis of NL, chronic and newly formed keloid tissue ( Figure 3 ). There was increased expression of ASPN and Cadherin in some dermal and endothelial cells of chronic and new keloid lesion compared to NL skin ( Figure 3A ,B). BMP1 was also expressed strongly in some dermal cells of lesional skin compared to NL and new keloid lesion ( Figure 3C ). RUNX2 showed moderate expression in the epidermis of NL, chronic and newly formed keloid tissue, but had increased expression of distinct dermal cells in chronic keloid and newly formed keloid compared to NL skin ( Figure 3D ).
We also performed two-colour immunofluorescence for RUNX2
and COL10A1 to determine co-expression of this transcription factor with the cells producing articular cartilage (type 10A collagen). Our results showed many COL10A1 + cells contained RUNX2 + nuclei (white 
arrows) in the dermis of chronic keloid and new keloid lesion compared to NL skin ( Figure 3E ).
| DISCUSSION
Keloids have previously been characterized by an abundance of disorganized type I and III collagen bundles in the extracellular matrix (ECM). [6] Through proliferation and production of collagens I/III, dermal fibroblasts have been proposed as the main cellular element implicated in the pathogenesis of keloid. [14, 15] Syed et al. [16] observed that keloid fibroblasts from the growing margin of keloid have elevated production of collagen I and collagen III compared with other lesional sites. Overexpression of TGF-β isoforms and TGF-β receptors has been detected in keloids and keloid-derived fibroblasts, which suggest that excess fibroplasia is regulated by TGF-β cytokines.
[2]
The keloids we profiled in this study were large and hard exophytic growths, corresponding to Stages II-IV in a recent classification scheme. [5] All lesions had a prominent dermal cellular component of spindle-shaped cells, but also acellular areas with enlarged collagen bundles. A small fraction of the spindle-shaped cells stained for Ki67, indicating ongoing proliferative activation, whereas Ki67 + dermal cells were not common in NL skin biopsies (data not shown). These lesions fit described diagnostic criteria for keloids by histopathology, but they are more cellular than many others described in the literature. [2] However, cells are not highly proliferative as might be seen in a fibrosarcoma. In molecular terms, our chronic keloids had mean upregulation of collagen I by 31-fold and collagen III by 22-fold vs NL controls, along with an increase of TGFβ3 by ninefold (Table S1) , fitting with the general concept of excess production of expected dermal collagens. We also detected a marked increase (44-fold) in IGF-2 (somatomedin a) mRNA and a 12-fold increase in IGF-1 (somatomedin c), which are key growth factors for connective tissue and epithelial cells, both acting through the IGF-1 receptor (Table 1A) .
While these are impressive changes, the scope of gene alterations and the magnitude of change were even greater for connective tissue molecules not normally associated with dermal wound healing.
These include (i) collagen 10A1, a short-chain minor collagen of cartilage formation [17] that is associated with events in the later stages of endochondral bone formation; (ii) ASPN, also known as periodontal ligament-associated protein 1 (PLAP1) belongs to a family of leucinerich repeat (LRR) proteins associated with the cartilage matrix [18] ; (iii) CDH11, a cell surface glycoprotein that mediate Ca keloid lesion and a few in NL skin. Size bar=100 μm bone cell differentiation and bone formation [19] ; (iv) Bone morphogenic protein 1 (BMP1), this locus encodes a protein that is capable of inducing formation of cartilage in vivo [20] ; (v) SPP1, which belongs to the small integrin-binding ligand N-linked glycoprotein (SIBLING) family of secreted phosphoproteins, is involved in the anchoring of osteoclasts to the mineral of bone matrix, [21] (vi) Runt-related transcription factor 2 (RUNX2), which is expressed in adult bone marrow, thymus and peripheral lymphoid organs, [22] has a primary role in the differentiation of osteoblasts [23] and hypertrophy of cartilage at the growth plate, cell migration and vascular invasion of bone. In chondrogenic and osteoblastic cell lines, RUNX2 has been demonstrated to transactivate type 1 collagen and type X collagen (Col10A1).
[ 24] Upstream activation of chondrogenic differentiation has been found to be mediated by RUNX2. [25, 26] Thus, the molecular fingerprint of cellular activation in keloids is more related to differentiation of cartilage and bone connective tissues than dermal connective tissue and may be mediated by RUNX2
overexpression. The association with IGF-1 and IGF-2 over-expression is intriguing, as the IGF-1 receptor mediates skeletal growth and development as a primary action (IGF-1 and IGF-2 mutations are responsible for growth restriction [27] ) Previous work has identified over-expression of IGF-1 receptors on connective tissue cells in keloid lesions.
[28]
The gene expression changes we observe lead to excess pro- among 32 upregulated DEGs, [10] also pointing to aberrant chondrogenic differentiation. The high expression of RUNX2 is a likely key inducer of this aberrant differentiation program, [24] and it might be a targetable axis for future therapy.
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